1月21日 - ** 癌症测试开发商Lucid Diagnostics LUCD.O的股价盘前上涨3.31%至1.25美元
** 该公司表示， (link) 它已与美国退伍军人事务部签订了一份EsoGuard测试合同，该测试可检测与早期食管癌有关的DNA变化。
** 食管癌通常始于长期胃灼热造成的损害，EsoGuard 采用快速的诊疗程序收集细胞并筛查这些变化，据LUCD介绍。
** 称全国各地的退伍军人医院和诊所现在都能以与医疗保险相匹配的价格购买该检测产品，从而使 900 多万人获得早期食管癌筛查的机会
** 2025 年，LUCD 股价上涨约33%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.